NCT05988008View on ClinicalTrials.gov

A Study of CCX168 in Japanese and Caucasian Healthy Adult Males

PHASE1CompletedINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

October 23, 2017

Primary Completion Date

January 26, 2018

Study Completion Date

September 20, 2018

Conditions

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions

DRUG

CCX168

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

130-0004

Sumida Hospital, SOUSEIKAI Global Clinical Research Center, Sumida City

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY